Pre-surgery chemo-radiation for rectal cancer without MGMT
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma confirmed by biopsy, and your tumor testing must show MSS and “MGMT silenced” (no MGMT protein and MGMT gene turned off).
- Your cancer must be locally advanced but still removable with curative surgery (possibly including a more extensive pelvic surgery).
- Your body is strong enough for treatment: performance status 0–1 (up and active most of the day) and you must have blood counts good enough for chemo.
- Your scans must show no spread to other organs (no metastatic disease) and specific imaging features must match the trial’s “locally advanced” definitions.
- You must be able to provide stored tumor tissue for central lab testing.
- You must not have certain exclusions, including prior pelvic radiation and a body metabolism problem called DPD deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests whether a newer approach can treat early-stage rectal cancer without removing the whole rectum, aiming to preserve bowel function. It compares different treatment options to see which is safest and most effective.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.